Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole-Body Hyperthermia + Standard Therapy in Metastatic Pancreatic Cancer
NCT07711067Phase 3Not yet recruiting
- Sponsor
- ElmediX
- Start
- Oct 2026
- Primary completion
- Mar 2030
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by ElmediX. Primary endpoints: Overall Survival at 12 months and Safety and Tolerability at 10 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07711067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711067.